Atlas Trials

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Clinical trial NCT05245994 · UNKNOWN

Trial details

NCT number
NCT05245994
Sponsor
Li Zhang, MD
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung CancerSmall Cell Lung CancerDurvalumab
Start date
2021-08-21
Primary completion
2023-05-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.